ZyVersa Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 7
- Market Cap
- -
- Website
- http://www.zyversa.com
- Introduction
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- ZyVersa Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06489340
- Locations
- 🇺🇸
Clinical Advancement Center, PLLC, San Antonio, Texas, United States
News
FDA Authorizes Emergency Compassionate Use of VAR 200 for Ultra-Rare ApoCII Amyloidosis
The FDA has authorized emergency compassionate use of ZyVersa Therapeutics' VAR 200 for a patient with ApoCII amyloidosis, an ultra-rare kidney disease with no effective treatment options.
ZyVersa Therapeutics Initiates Phase 2a Trial for First-in-Class Diabetic Kidney Disease Treatment VAR 200
ZyVersa Therapeutics has activated its first clinical site in San Antonio, Texas, to begin patient recruitment for a Phase 2a trial of VAR 200, a potential first-in-class treatment targeting renal lipotoxicity in diabetic kidney disease.
ZyVersa's IC 100 Shows Promise as Disease-Modifying Treatment for Parkinson's Disease
New research validates that microglia-driven inflammation plays a pivotal role in Parkinson's disease progression, with studies showing IC 100 can block NLRP1 inflammasome activation and reduce toxic alpha-synuclein accumulation.
ZyVersa Therapeutics to Present Kidney Disease Drug VAR 200 at JPM Healthcare Conference 2025
ZyVersa Therapeutics' CEO, Stephen C. Glover, will attend the JPM Healthcare Conference in January 2025 to discuss the company's pipeline.
ZyVersa Highlights Data on Inflammasome Inhibition for Type 2 Diabetes Prevention
ZyVersa Therapeutics highlights data showing inflammasome inhibition protects pancreatic islet beta cells, preventing obesity progression to type 2 diabetes.